May 24, 2017European Heart Journal
Pregnancy in hypertrophic cardiomyopathy
Key result
Among 60 pregnant women with hypertrophic cardiomyopathy, major adverse cardiovascular events occurred in approximately 23%, with no maternal deaths over 6 months of post-partum follow-up.
Population
60 pregnant women with hypertrophic cardiomyopathy from an international cohort.
Design
Editorial
Follow-up
6 months after delivery
Authors
Discussion
Loading...
Member takes
Implication
Pregnancy in women with hypertrophic cardiomyopathy carries a ~23% risk of MACE, which is largely dependent on pre-pregnancy NYHA functional class, though maternal mortality is rare.
Structured PICO
P
Population
60 pregnant women with hypertrophic cardiomyopathy (left ventricular wall thickness ≥15 mm) followed for 6 months after delivery.
O
Outcome
Major adverse cardiovascular event (MACE) defined as death, heart failure, arrhythmia, or thrombo-embolic eventcomposite
Pregnancy in women with hypertrophic cardiomyopathy carries a ~23% risk of MACE, which is largely dependent on pre-pregnancy NYHA functional class, though maternal mortality is rare.
Limitations
- Neither genotyping nor family history information was available.
- Approximately 14% of women had antecedent hypertension, raising the possibility that not all subjects had true sarcomeric HCM.
- The left ventricular outflow tract gradient was not obtained quantitatively, so the severity of obstruction was unknown.
- Neither genotyping nor family history information was available
- ~14% of women included had antecedent hypertension, raising the possibility that not all subjects had true sarcomeric HCM
- The left ventricular outflow tract gradient was not obtained quantitatively, so severity of obstruction was unknown
Cite This Study
Anjali Owens (2017) conducted an editorial in Hypertrophic cardiomyopathy (n=60). Pregnancy was evaluated on Major adverse cardiovascular event (MACE) defined as death, heart failure, arrhythmia, or thrombo-embolic event. Among 60 pregnant women with hypertrophic cardiomyopathy, major adverse cardiovascular events occurred in approximately 23%, with no maternal deaths over 6 months of post-partum follow-up.